Organic compounds -- part of the class 532-570 series – Organic compounds – Chalcogen in the nitrogen containing substituent
Reexamination Certificate
2006-08-29
2006-08-29
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Chalcogen in the nitrogen containing substituent
C544S230000, C544S236000, C544S253000, C544S284000, C540S600000, C514S266230, C514S258100, C514S252170, C514S217060, C514S248000
Reexamination Certificate
active
07098330
ABSTRACT:
This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rxand Ryare taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2and R2′are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
REFERENCES:
patent: 5436233 (1995-07-01), Lee et al.
patent: 5658902 (1997-08-01), Ahn et al.
patent: WO 95/15758 (1995-06-01), None
patent: WO 97/20820 (1997-06-01), None
patent: WO 98/14450 (1998-04-01), None
patent: WO 99/32460 (1999-07-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/21955 (2000-04-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 02/18346 (2002-03-01), None
Heutink P.Untangling tau-related dementia.Hum Mol Genet. Apr. 12, 2000;9(6):979-86.
Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.Jpn J Pharmacol. Oct. 2000;84(2):101-12.
Eldar-Finkelman et al Expert Opinion on Investigational Drugs (Ashley Publications), 2003, vol. 12, No. 9, pp. 1511-1519.
Anonymous, Expert Opinion on Therapeutic Patents (Ashley Publications), 2004, vol. 14, No. 3, pp. 439-443.
Coleman, Robert A. “The Biological Evaluation of New Compounds” in Medicinal Chemistry: Pricciples and Practice, King, Frank D. ed, Royal Society of Chemistry, 1994, pp. 53-66.
Ganellin, C. Robin, “Past Approaches to Discovering New Drugs as Medicines”, in Medicinal Chemistry: Pricciples and Practice, King, Frank D. ed, Royal Society of Chemistry, 1994, pp. 189-205.
Jambhekar, Sunil S., “Biopharmaceutical Properties of Drug Substances” in Principles of Medicinal Chemistry, 4ed. Foye, William O. et al Williams & Wilkins, 1995, Williams & Wilkins, 1995, Baltimore, pp. 12-24.
Traxler, P., et al., “Use of Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines”, J. Med. Chem., 40:3601-3616 (1997).
Bebbington David
Binch Hayley
Charrier Jean-Damien
Davies Robert J.
Golec Julian M. C.
McKenzie Thomas C.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
LandOfFree
Pyrazolylamine substituted quinazoline compounds useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolylamine substituted quinazoline compounds useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolylamine substituted quinazoline compounds useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668399